Elon Musk is hoping to put resources into an opponent to his cerebrum figuring startup Neuralink.
The billionaire has approached the CEO of Synchron, which is developing brain implants, about potentially taking a stake according to Reuters, citing four sources familiar with the matter.
It is unclear whether the CEO of Thomas Oxley Synchron will accept the offer, the report said.
Neuralink is trying to catch up with Synchron which in July made the first U.S. test of its technology. The preliminary included embedding its gadget in the first of six patients. In the principal patient, ALS is a dynamic neurodegenerative sickness that influences nerve cells in the mind and spinal line.
The device aims to translate a patient’s thoughts into action, including browsing online and communicating via email via commands sent to the computer.
Synchron’s human trial is its second. Bloomberg reported that the first was conducted in Australia with four patients who had no negative side effects and were able to communicate and shop online.
Neuralink established in 2016, presently can’t seem to start human preliminaries. It is unclear at what stage a company is applying with the US Food and Drug Administration for approval to begin human trials, the report said.
Both the startups want to create technology that transforms the thoughts of the common man into speech or actions of people with speech disabilities.
Former and current employees told Reuters that Musk was disappointed by the slow progress on Neuralink’s technology and expressed his dismay after reaching out to Oxley. Tension within Neuralink is nothing new as Fortune has previously reported.
Max Hodak the former chairman of Neuralink left the company after serving as its leader since its inception and is now an investor in Synchron.